Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline.

@article{Earle2002NeoadjuvantOA,
  title={Neoadjuvant or adjuvant therapy for resectable gastric cancer? A practice guideline.},
  author={Craig C. Earle and Jean Alfred Maroun and Lisa Zuraw},
  journal={Canadian journal of surgery. Journal canadien de chirurgie},
  year={2002},
  volume={45 6},
  pages={438-46}
}
OBJECTIVE To make recommendations on the use of neoadjuvant or adjuvant therapy in addition to surgery in patients with resectable gastric cancer (T1-4, N1-2, M0). OPTIONS Neoadjuvant or adjuvant treatments compared with "curative" surgery alone. OUTCOMES Overall survival, disease-free survival, and adverse effects. EVIDENCE The MEDLINE, CANCERLIT and Cochrane Library databases and relevant conference proceedings were searched to identify randomized trials. VALUES Evidence was selected… CONTINUE READING

2 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Evidence was selected and reviewed by one member of the Cancer Care Ontario Practice Guidelines Initiative ( CCOPGI ) Gastrointestinal Cancer Disease Site Group and methodologists .
Evidence was selected and reviewed by one member of the Cancer Care Ontario Practice Guidelines Initiative ( CCOPGI ) Gastrointestinal Cancer Disease Site Group and methodologists .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
Evidence was selected and reviewed by one member of the Cancer Care Ontario Practice Guidelines Initiative ( CCOPGI ) Gastrointestinal Cancer Disease Site Group and methodologists .
Evidence was selected and reviewed by one member of the Cancer Care Ontario Practice Guidelines Initiative ( CCOPGI ) Gastrointestinal Cancer Disease Site Group and methodologists .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
There is insufficient evidence from randomized trials to recommend neoadjuvant chemotherapy , or neoadjuvant or adjuvant radiotherapy or immunotherapy , either alone or in combination , outside a clinical trial .
All Topics